Myocardial transfection with hypoxia inducible factor-1α via an adenoviral vector during coronary artery bypass grafting

Kilian, Eckehard; Sadoni, Sebastian; Bengel, Dietmar; Vicol, Calin; Pillai, Reshmi; Hetzer, R.; Reichart, B.

doi:10.1055/s-2007-967703

Cited by 1 publication

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Angiogenic gene therapy (AGENT) which results in sustained production of the angiogenic protein could overcome the unfavorable results of using angiogenic proteins which showed short duration of effect. 31,32 In this regard, over the past two decades several clinical trials have been performed using VEGF, [19][20][21][22][23][24][25][26][27][28]33,34,40 FGF, 18,31,32 HIF, 35 and HGF. 36 Walter and colleagues, used phVEGF-2 plasmid (100 or 200 μg per stent)-coated BiodivYsio phosphorylcholine polymer stents vs uncoated stents that were deployed in a randomized blinded fashion in iliac arteries of 40 normocholesterolemic and 16 hypercholesterolemic rabbits.…”

Section: Methodsmentioning

confidence: 99%

“…The results showed remarkable improvement in the perfusion rate in the ischemic area. Although, this study revealed the safety and viability of Ad2‐HIF injection in the myocardium, but due to small sample size, the results should be confirmed by larger series studies …”

Section: Review Of Literaturementioning

confidence: 99%

“…However, the improvement in ETT less than or equal to 10 minutes was significantly more in Ad5-FGF4-administrated group than the placebo. 35 Yang and colleagues in a phase I clinical trial studied the arterial gene transfer of Ad-HGF in 18 patients with CAD (group A: 5 × 10 9 pfu, n = 6; group B: 1 × 10 10 pfu, n = 6; and group C: 2 × 10 10 pfu, n = 6). Therefore, it seems that the Ad5-FGF4 gene therapy is a new and almost safe therapeutic approach to the treatment of angina pectoris.…”

Section: Adenoviral Vectors As Carriersmentioning

confidence: 99%

“…Although, this study revealed the safety and viability of Ad2-HIF injection in the myocardium, but due to small sample size, the results should be confirmed by larger series studies. 35 Yang and colleagues in a phase I clinical trial studied the arterial gene transfer of Ad-HGF in 18 patients with CAD (group A: 5 × 10 9 pfu, n = 6; group B: 1 × 10 10 pfu, n = 6; and group C: 2 × 10 10 pfu, n = 6). The trial did not report any serious adverse effects, such as fever, hemodynamic changes, arrhythmia, and other possible adverse events related to the Ad-HGF gene through 7, 21, and 35 days after the operation indicating that Ad-HGF is safe and feasible.…”

Section: Adenoviral Vectors As Carriersmentioning

confidence: 99%

See 3 more Smart Citations

Gene therapy in cardiovascular diseases: A review of recent updates

Gorabi

Hajighasemi

Tafti

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Gene therapy is considered as a promising approach for treating cardiac dysfunction. In this review, we evaluated the clinical trials assessing gene therapy in cardiovascular diseases (CVD) from 2000 to 2017. PubMed and ClinicalTrials.gov (only English language) were searched for clinical trials published between January 2000 and May 2017, using the search terms "gene transfer" OR "gene therapy" and "cardiovascular diseases" and related terms. The trials with sample size lower than 10 patients were excluded. Twenty-six clinical trials on human and animals, including 1543 patients were listed and evaluated. The sample size in 14 trials was lower than 100 patients and in seven trials lower than 20 patients. Eleven trials used plasmid DNA and eight trials used adenovirus, one study used plasmid DNA, adenovirus, and liposome. We detected that gene therapy was a safe approach and improved the symptoms of CVD; however, the effect of gene therapy on the cardiac dysfunction is controversial.

show abstract